US-based life sciences tools company Unchained Labs has secured $25m in a series A round led by Novo Ventures, the corporate venturing arm of pharmaceutical company Novo.
The round also featured Canaan Partners and TPG Biotech.
Concurrent to revealing the series A round, Unchained also disclosed its first acquisition with Optim, an analytical instrument that enables drug developers to monitor protein stability, from life sciences company Avacta for an undisclosed amount. Optim been sold to more than 60 biopharmaceutical companies and academic researchers so far.
Unchained Labs bills itself as a life sciences tools company that will focus on acquiring businesses and products in the sector.
Tim Harkness, founder and chief executive of Unchained Labs, said: “The right group of people can accomplish anything, and we are starting out with fantastic investors and employees who are committed to creating something special together.
“Optim is a one-of-a-kind product that will provide a solid foundation for us.”